Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-08-14), Usana Health Sciences's 1-Year Sharpe Ratio is -0.55.
Usana Health Sciences (NYSE:USNA) 1-Year Sharpe Ratio Explanation
The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.
The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.
Usana Health Sciences 1-Year Sharpe Ratio Related Terms
USNA vs ENHA, NATR, AMNF: 1-Year Sharpe Ratio Comparison
For the Packaged Foods subindustry, Usana Health Sciences's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Usana Health Sciences 1-Year Sharpe Ratio vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Usana Health Sciences's 1-Year Sharpe Ratio distribution charts can be found below:
* The bar in red indicates where Usana Health Sciences's 1-Year Sharpe Ratio falls into.
Usana Health Sciences 1-Year Sharpe Ratio Calculation
The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.
Usana Health Sciences (USNA) has a 1-Year Sharpe Ratio of -0.55 as of Aug. 14, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Usana Health Sciences and its competitors.
Is Usana Health Sciences' 1-Year Sharpe Ratio too high?
Usana Health Sciences' current 1-Year Sharpe Ratio is -0.55. Overall, Usana Health Sciences has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Usana Health Sciences' 1-Year Sharpe Ratio compare to ENHA and NATR?
Usana Health Sciences' 1-Year Sharpe Ratio of -0.55 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Consumer Packaged Goods company?
A good 1-Year Sharpe Ratio depends on the Consumer Packaged Goods industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Usana Health Sciences and its competitors. Usana Health Sciences's current 1-Year Sharpe Ratio is -0.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Usana Health Sciences stock overvalued right now?
Based on GuruFocus' analysis, Usana Health Sciences (USNA) is currently considered Possible Value Trap. The stock's GF Value™ is $40.72, compared to a current price of $13.63 — trading 66.5% below its estimated fair value. The current 1-Year Sharpe Ratio is -0.55. Usana Health Sciences' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Usana Health Sciences (USNA), the current 1-Year Sharpe Ratio is -0.55 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Usana Health Sciences (USNA) Overvalued in 2026?
Based on GuruFocus' analysis, Usana Health Sciences stock appears to be undervalued.
The current stock price of $13.63 is trading 66.5% below its estimated GF Value™ of $40.72.
GuruFocus considers Usana Health Sciences to be Possible Value Trap.
Key valuation signals for USNA:
1-Year Sharpe Ratio: -0.55
GF Value™: $40.72 vs. price of $13.63 (66.5% below fair value)
No single metric tells the full story. See the USNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
66GF Score
Get the complete analysis for USNA
1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
USNA has been successfully added to your 
